The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
SOUTH SAN FRANCISCO, Calif., Jan. 28, 2020 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced the dosing of the first ...
- AL003 is Alector’s second program targeting Alzheimer’s disease and its third program in the clinic SOUTH SAN FRANCISCO, Calif., April 01, 2019 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a ...
Alector, Inc.ALEC announced the initiation of the phase I INTERCEPT study on AL003 for the treatment of Alzheimer's disease. The randomized, double-blind, placebo-controlled, dose escalation study ...
- Phase 1b study of AL003 will enroll approximately 12 Alzheimer’s disease patients to assess safety, pharmacokinetics and pharmacodynamics, and monitor target specific biomarkers SOUTH SAN FRANCISCO, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results